Clinical Cancer Research The Future of Cancer Research: Science and Patient Impact
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diab, S. G.
Right arrow Articles by Rowinsky, E. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diab, S. G.
Right arrow Articles by Rowinsky, E. K.
Clinical Cancer Research Vol. 5, 299-308, February 1999
© 1999 American Association for Cancer Research

Clinical Trials

A Phase I and Pharmacokinetic Study of Losoxantrone and Paclitaxel in Patients with Advanced Solid Tumors1

Sami G. Diab2, Sharyn D. Baker, Amita Joshi, Howard A. Burris3, Patrick W. Cobb3, Miguel A. Villalona-Calero, S. Gail Eckhardt, Geoffrey R. Weiss, Gladys I. Rodriguez, Ronald Drengler, Maura Kraynak4, Lisa Hammond, Michael Finizio, Daniel D. Von Hoff and Eric K. Rowinsky

The University of Texas Health Science Center at San Antonio [S. G. D., G. R. W., R. D.], Institute for Drug Development and Cancer Therapy and Research Center [S. D. B., M. A. V-C., S. G. E., G. I. R., M. K., L. H., D. D. V. H., E. K. R.], and Brooke Army Medical Center [H. A. B., P. W. C.], San Antonio, Texas 78234; and DuPont Pharmaceuticals Company, Wilmington, Delaware 19880 [A. J., M. F.]

A Phase I and pharmacological study was performed to evaluate the feasibility, maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetics of the anthrapyrazole losoxantrone in combination with paclitaxel in adult patients with advanced solid malignancies. Losoxantrone was administered as a 10-min infusion in combination with paclitaxel on either a 24- or 3-h schedule. The starting dose level was 40 mg/m2 losoxantrone and 135 mg/m2 paclitaxel (as a 24- or 3-h i.v. infusion) without granulocyte colony-stimulating factor (G-CSF). Administration of these agents at the starting dose level and dose escalation was feasible only with G-CSF support. The following dose levels (losoxantrone/paclitaxel, in mg/m2) of losoxantrone and paclitaxel as a 3-h infusion were also evaluated: 50/135, 50/175, 50/200, 50/225, and 60/225. The sequence-dependent toxicological and pharmacological effects of losoxantrone and paclitaxel on the 24- and 3-h schedules of paclitaxel were also assessed. The MTD was defined as the dose at which >50% of the patients experienced DLT during the first two courses of therapy. DLTs, mainly myelosuppression, occurring during the first course of therapy were noted in four of six and five of eight patients treated with 40 mg/m2 losoxantrone and 135 mg/m2 paclitaxel over 24 and 3 h, respectively, without G-CSF. DLTs during the first two courses of therapy were observed in one of six patients at the 50/175 (losoxantrone/paclitaxel) mg/m2 dose level, two of four patients at the 50/200 mg/m2 dose level, one of four patients at the 50/225 mg/m2 dose level, and two of five patients at the 60/225 mg/m2 dose level. The degree of thrombocytopenia was worse, albeit not statistically significant, when 24-h paclitaxel preceded losoxantrone, with a mean percentage decrement in platelet count during course 1 of 80.7%, compared to 43.8% with the reverse sequence (P = 0.19). Losoxantrone clearance was not significantly altered by the sequence or schedule of paclitaxel. Cardiac toxicity was observed; however, it was not related to total cumulative dose of losoxantrone. An unacceptably high rate of DLTs at the first dose level of 40 mg/m2 losoxantrone and 135 mg/m2 paclitaxel administered as either a 24- or 3-h i.v. infusion precluded dose escalation without G-CSF support. The addition of G-CSF to the regimen permitted further dose escalation without reaching the MTD. Losoxantrone at 50 mg/m2 followed by paclitaxel (3-h i.v. infusion) at 175 mg/m2 with G-CSF support is recommended for further clinical trials.




This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
U. D. Renner, G. Piperopoulos, R. Gebhardt, G. Ehninger, and K.-P. Zeller
The Oxidative Biotransformation of Losoxantrone (CI-941)
Drug Metab. Dispos., April 1, 2002; 30(4): 464 - 478.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
A. S. Joshi, H. J. Pieniaszek Jr., E. E. Vokes, N. J. Vogelzang, A. F. Davidson, L. E. Richards, M. F. Chai, M. Finizio, and M. J. Ratain
Elimination Pathways of [14C]Losoxantrone in Four Cancer Patients
Drug Metab. Dispos., February 1, 2001; 29(2): 96 - 99.
[Abstract] [Full Text]

Home page
 JCOHome page
L. A. Hammond, J. R. Eckardt, S. D. Baker, S. G. Eckhardt, M. Dugan, K. Forral, P. Reidenberg, P. Statkevich, G. R. Weiss, D. A. Rinaldi, et al.
Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies
J. Clin. Oncol., August 1, 1999; 17(8): 2604 - 2604.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.